BT-474 is a cell line exhibiting epithelial morphology that was isolated from a solid, invasive ductal carcinoma of the breast obtained from a 60-year-old, White, female breast cancer patient. Use these cells in your cancer research.

BT-474 Clone 5 is an epithelial-like cell line clone that was originally isolated from the mammary gland of a 60-year-old, White female patient with ductal carcinoma.

BT-474-Luc2 CAR-T Target Luciferase Reporter Cells can be used as a target cancer cell for in vitro killing assay by HER2 CAR-T cells (tested at ATCC). BT-474 naturally expresses high levels of the gene HER2 (verified at ATCC).

Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Population: Caucasian. Doubling time: 3.5 days (PubMed= 9671407); 78 hours (PubMed= 25984343); …

e model for studying hormone-responsive breast cancers. BT-474 cells are also characterized by the overexpression of HER2/neu (human epidermal growth factor receptor 2), a protein that is amplified and plays a critical role in the pathogenesis and p.

May 1, 2020 · The use of models like BT-474 that can bridge the gap between preclinical model and cancer patient is crucial. Optimization of our BT-474 breast cancer model in NSG mice has been a significant advancement of our validated breast tumor models, and we are continuing to evaluate other HER2 targeted therapies, such as Herceptin, in the BT-474 model.

BT-474 is a human breast cancer cell line that was established from a primary tumor in a patient with breast cancer. It is commonly used as a model for studying the biology of breast cancer, which is the second most common cancer in women worldwide and is associated with a significant mortality rate.

Learn more about this cell line in our scientific spotlights: The BT-474 cell line has a long history, but many of us thought it had run its natural course and was quickly becoming obsolete.

The trastuzumab-conditioned BT-474.R cell lines were established by culturing the BT-474 cell line in the appropriate medium supplemented with 15 μg/ml of recombinant humanized monoclonal HER2 antibody, trastuzumab (Herceptin, Genentech, USA).

Breast ductal carcinoma General information RNA-seq STR profile HLA Typing Mutations CellDive-ID 64 DSMZ ACC-64 Cell line name BT-474 SpeciesHomo sapiens (human) Cell type breast ductal carcinoma Incubation medium 80% RPMI 1640 + 20% h.i. FBS + 10 æg/ml human insulin + 2 mM L-glutamine Morphology adherent patches of epithelial cells; individual colonies with a thick center and a thin smooth ...